Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Cancer Res. 2015 Jan 16;75(6):1035–1045. doi: 10.1158/0008-5472.CAN-13-1625

Figure 7. ERBB3 knockdown partially affects the viability of EGFR mutant, human lung cancer cell lines.

Figure 7

(A) Western blots of protein lysates derived from EGFR mutant lung cancer cell lines probed with antibodies as indicated. (B) H3255, PC9 and PC9BRc1 cells were transiently transfected with pools of siRNAs against EGFR, ERBB3, GAB1, GAB1+ERBB3, GAB1+GAB2, GAB1+GAB2+ERBB3 or a scrambled siRNA control as indicated. Three days after transfection, cells were lysed in RIPA buffer and proteins were analyzed by Western blotting and cell viability was examined using the CellTiter blue assay. Experiments were performed at least three times for each cell line. (C) Viability of PC9 and H3255 cells after transfection with pools of siRNAs against EGFR, ERBB3, EGFR+ERBB3, ERBB2 and ERBB2+ERBB3. Cell viability was measured using the Cell Titer Blue Assay. (D) Growth inhibition in PC9 cells upon ERBB3 knockdown treated with varying concentrations of erlotinib as indicated. *indicates p-value ≤ 0.05, *** indicates p-value ≤ 0.01. NS: not significant.